How Does Souvenaid® Work?

There is a growing body of evidence showing that people with early Alzheimer’s disease have low levels of several nutrients – omega-3 fatty acids, B vitamins and antioxidants are just some – despite eating a normal diet.1-2  These nutrients play an important role in brain health and memory function.

Souvenaid® has been designed to supply specific nutrients to aid the naturally occurring processes in the brain, that are involved in maintaining the brain’s integrity. The unique combination of nutrients that Souvenaid® contains, work together to produce a greater effect than when taking them individually. Although, found naturally in food, the amount of these specific nutrients found in Souvenaid® would be difficult to achieve through a normal diet.

SOUVENAID® – CLINICALLY PROVEN

Souvenaid’s® efficacy was originally established in 2 clinical trials, Souvenir I and Souvenir II, which demonstrated memory improvement in patients with mild to moderate Alzheimer’s disease taking Souvenaid® once-daily over 12 and 24 weeks, respectively.3,4

A third trial was then conducted which is known as LipiDidiet. It included patients with mild-to-moderate Alzheimer’s disease and found that Souvenaid® improved everyday thinking, functional ability and memory performance in the people who drank it every day for 2 years.5

More information on each study can be found in the below tabs.

An independent EU study, funded by the European Commission, investigated the long term use and impact of Souvenaid on memory and cognitive function in the very early stages of Alzheimer’s disease, including Mild Cognitive Impairment. This was called the LIPIDIDIET study.6

The LipiDiDiet trial concluded that Souvenaid is clinically proven to slow progression of Mild Cognitive Impairment in multiple aspects including slowing the progression of memory and cognitive decline by 60 per cent. The clinical data also indicates that Souvenaid reduced brain shrinkage by 33 per cent and reduced the loss of everyday task performance by 45 per cent.6

No other nutritional product has ever shown these results – Souvenaid is scientifically proven with the world’s first successful long term clinical trial in Mild Cognitive Impairment using a nutritional intervention.6

Watch video

Based on the results of Souvenir I and II, the independent, European Commission- funded the LipidiDiet trial focused on the long term (2 year) use of Souvenaid® for cognitive function in very early stages of Alzheimer’s disease. The LipidiDiet study involved 311 patients with prodromal Alzheimer’s disease (very early form of Alzheimer’s) who were again randomly assigned to receive either Souvenaid® or the control product. The patients and investigators were not informed as to which product they were receiving.

The LipidiDiet trial concluded that in people with prodromal Alzheimer’s disease, the consumption of Souvenaid® was associated with a reduction in brain shrinkage, as well as the stabilisation of everyday cognitive and functional performance.5

The Souvenir II trial involved 259 patients with mild Alzheimer’s disease from several countries across Europe. As in the previous study, these patients were not taking any medication for their Alzheimer’s disease and they were randomly assigned to receive either Souvenaid® or the control product. The patients and investigators were not informed as to which product they were receiving.

Various parameters were assessed using a comprehensive collection of tests at the beginning of the trial, at 12 weeks and again at the end of the trial. Patients who were taking Souvenaid®, showed improved nutritional status over the 24 week period. As with the previous trial, analysis of bloods was used to confirm that the patients were taking Souvenaid® regularly. There were no side effects that were thought to be related to the product.

The Souvenir II trial concluded that that in people with mild Alzheimer’s disease, the consumption of Souvenaid® was associated with improved memory performance.4

This trial was carried out in several countries across Europe and in the USA. The 225 patients were all in the mild stage of their disease and were not taking any other Alzheimer medication. Patients were randomly assigned to one of two groups, receiving either Souvenaid® or the control product which was similar in flavour and appearance but lacked the key ingredients. Neither the investigators, nor the patients themselves, knew who was taking which product.

A wide range of test parameters was assessed at the beginning of the trial and after 12 weeks. The patients taking Souvenaid® showed improvements in their nutritional status at the end of the 12 week period. Analysis of bloods confirmed that the patients were taking the product regularly and there were no side effects that were attributed to Souvenaid®.

Souvenaid® improved the nutritional status of patients with mild Alzheimer’s disease, after 12 weeks. The results also showed that the product was well-tolerated and compliance was high.

The Souvenir I trial concluded that that in people with mild Alzheimer’s disease, the consumption of Souvenaid® was associated with improved memory performance.3

What if i still have questions?

If you feel that you still have questions, please take a look at our Frequently Asked Questions, send us an email or
call our Souvenaid® team on 1800 319 420. Buy Souvenaid online Request a Sample Contact Us

  1. Lopes da Silva S et al, Alzheimer’s & Dementia 2014; 10(4); 485-502
  2. Mi W et. al Nutrition 29:1080-1089
  3. Scheltens P et al. Alzheimers Dement 2010; 6: 1–10.e1.
  4. Scheltens P et al. J Alzheimers Dis 2012; 31: 225–236
  5. Soininen H et al. Lancet Neurol 2017; 16: 965–975.
  6. Soininen H, Solomon A, Visser PJ, et al. 36-month LipiDiDietmultinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimer’s Dement. 2020;1–12.
    + when taken daily for 3 years 

* It is important to acknowledge that the primary outcome of this study did not reach statistical significance, due to lower cognitive decline in the populations than expected. It is anticipated that the positive trend will continue and reach statistical significance at year 3 (publication expected mid 2020). The positive results described come from secondary outcome measures